These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 31846866)

  • 1. Disease activity impacts disability progression in primary progressive multiple sclerosis.
    Marrodan M; Bensi C; Pappolla A; Rojas JI; Gaitán MI; Ysrraelit MC; Negrotto L; Fiol MP; Patrucco L; Cristiano E; Farez MF; Correale J
    Mult Scler Relat Disord; 2020 Apr; 39():101892. PubMed ID: 31846866
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The natural history of early versus late disability accumulation in primary progressive MS.
    Koch MW; Greenfield J; Javizian O; Deighton S; Wall W; Metz LM
    J Neurol Neurosurg Psychiatry; 2015 Jun; 86(6):615-21. PubMed ID: 25091366
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The natural history of primary progressive multiple sclerosis.
    Koch M; Kingwell E; Rieckmann P; Tremlett H
    Neurology; 2009 Dec; 73(23):1996-2002. PubMed ID: 19996074
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The natural history of primary progressive multiple sclerosis: insights from the German NeuroTransData registry.
    Braune S; Bluemich S; Bruns C; Dirks P; Hoffmann J; Heer Y; Rouzic EM; Bergmann A;
    BMC Neurol; 2023 Jul; 23(1):258. PubMed ID: 37407914
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Smoking does not influence disability accumulation in primary progressive multiple sclerosis.
    Javizian O; Metz LM; Deighton S; Koch MW
    Eur J Neurol; 2017 Apr; 24(4):624-630. PubMed ID: 28239937
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mitoxantrone: a review of its use in multiple sclerosis.
    Scott LJ; Figgitt DP
    CNS Drugs; 2004; 18(6):379-96. PubMed ID: 15089110
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long term effect of delayed treatment on disability in patients with paediatric onset multiple sclerosis: A prospective Danish cohort study.
    Kopp TI; Blinkenberg M; Petersen T; Sorensen PS; Magyari M
    Mult Scler Relat Disord; 2020 May; 40():101956. PubMed ID: 32007654
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multiple Sclerosis Progressive Courses: A Clinical Cohort Long-Term Disability Progression Study.
    Cortesi PA; Fornari C; Capra R; Cozzolino P; Patti F; Mantovani LG
    Value Health; 2022 Sep; 25(9):1489-1498. PubMed ID: 35484029
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modelling the natural history of primary progressive multiple sclerosis.
    Harding KE; Wardle M; Moore P; Tomassini V; Pickersgill T; Ben-Shlomo Y; Robertson NP
    J Neurol Neurosurg Psychiatry; 2015 Jan; 86(1):13-9. PubMed ID: 24828900
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of the times of disability progression and related factors in patients with primary progressive multiple sclerosis from Argentina.
    Alonso R; Garcea O; Rojas JI; Alonso M; Lázaro L; López P; Casas M; Tkachuk V; Steinberg J; Barboza A; Martínez A; Ysrraelit C; Correale J; Marrodan M; Chertcoff A; Deri N; Miguez J; Patrucco L; Cristiano E; Pestchanker C; Silva E; Vrech C; Zanga G; Leguizamón F; Carnero Contentti E; Carra A; Mainella C; Silva BA
    Mult Scler Relat Disord; 2022 Feb; 58():103483. PubMed ID: 35032883
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Brain atrophy and physical disability in primary progressive multiple sclerosis: A volumetric study.
    Galego O; Gouveia A; Batista S; Moura C; Machado E
    Neuroradiol J; 2015 Jun; 28(3):354-8. PubMed ID: 26246109
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Changes in the Risk of Reaching Multiple Sclerosis Disability Milestones In Recent Decades: A Nationwide Population-Based Cohort Study in Sweden.
    Beiki O; Frumento P; Bottai M; Manouchehrinia A; Hillert J
    JAMA Neurol; 2019 Jun; 76(6):665-671. PubMed ID: 30882868
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Validating predictors of disease progression in a large cohort of primary-progressive multiple sclerosis based on a systematic literature review.
    Stellmann JP; Neuhaus A; Lederer C; Daumer M; Heesen C
    PLoS One; 2014; 9(3):e92761. PubMed ID: 24651401
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical and demographic characteristics of primary progressive multiple sclerosis in Argentina: Argentinean registry cohort study (RelevarEM).
    Alonso R; Quarracino C; Eizaguirre B; Cohen L; Silva B; Pita C; Rojas JI; Pappolla A; Miguez J; Patrucco L; Cristiano E; Vrech C; Volman G; Silva E; Barboza A; Deri N; Tkachuk V; Zanga G; Tavolini D; Saladino ML; Luetic G; Menichini ML; Carnero Contentti E; López P; Steinberg J; Divi P; Hryb J; Alves Pinheiro A; Carra A; Balbuena ME; Lázaro L; Fernández Liguori N; Garcea O;
    Neurol Sci; 2020 Nov; 41(11):3329-3335. PubMed ID: 32840711
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Progression rates and sample size estimates for PPMS based on the CLIMB study population.
    Raghavan K; Healy BC; Carruthers RL; Chitnis T
    Mult Scler; 2015 Feb; 21(2):180-8. PubMed ID: 25070676
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term disability trajectories in primary progressive MS patients: A latent class growth analysis.
    Signori A; Izquierdo G; Lugaresi A; Hupperts R; Grand'Maison F; Sola P; Horakova D; Havrdova E; Prat A; Girard M; Duquette P; Boz C; Grammond P; Terzi M; Singhal B; Alroughani R; Petersen T; Ramo C; Oreja-Guevara C; Spitaleri D; Shaygannejad V; Butzkueven H; Kalincik T; Jokubaitis V; Slee M; Fernandez Bolaños R; Sanchez-Menoyo JL; Pucci E; Granella F; Lechner-Scott J; Iuliano G; Hughes S; Bergamaschi R; Taylor B; Verheul F; Edite Rio M; Amato MP; Sajedi SA; Majdinasab N; Van Pesch V; Sormani MP; Trojano M
    Mult Scler; 2018 Apr; 24(5):642-652. PubMed ID: 28382837
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical impact of gender and age at onset on disease trajectory in primary progressive multiple sclerosis patients.
    Camerlingo S; Rubinstein F; Celia Ysrraelit M; Correale J; Carnero Contentti E; Rojas JI; Patrucco L; Leguizamon FDV; Tkachuk V; Fernandez Liguori N; Cristiano E; Mainella C; Zanga G; Carra A; Marrodan M; Martinez AD; Silva BA; Alonso R
    Mult Scler; 2024 Mar; 30(3):336-344. PubMed ID: 38247138
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modelling disease progression in relapsing-remitting onset multiple sclerosis using multilevel models applied to longitudinal data from two natural history cohorts and one treated cohort.
    Tilling K; Lawton M; Robertson N; Tremlett H; Zhu F; Harding K; Oger J; Ben-Shlomo Y
    Health Technol Assess; 2016 Oct; 20(81):1-48. PubMed ID: 27817792
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The timed 25-foot walk is a more sensitive outcome measure than the EDSS for PPMS trials: an analysis of the PROMISE clinical trial dataset.
    Koch MW; Mostert J; Repovic P; Bowen JD; Comtois J; Strijbis E; Uitdehaag B; Cutter G
    J Neurol; 2022 Oct; 269(10):5319-5327. PubMed ID: 35570237
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multiple sclerosis that is progressive from the time of onset: clinical characteristics and progression of disability.
    Andersson PB; Waubant E; Gee L; Goodkin DE
    Arch Neurol; 1999 Sep; 56(9):1138-42. PubMed ID: 10488816
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.